Keybanc Maintains Overweight on Toast, Raises Price Target to $26
Keybanc analyst Josh Beck maintains Toast (NYSE:TOST) with a Overweight and raises the price target from $25 to $26.
Amazon, Apple, Tesla, Root, Toast: Expense Review, Record Market Cap Gain, Earnings Draw Heavy Attention Today
The Dow Jones Industrial Average rose over 1,200 points on Thursday in its biggest one-day rally in over two years after a softer inflation report gave optimism to investors and traders that price rises may have peaked out.
Toast Stock Jumps In After Hours: What’s Driving The Action?
Toast Inc (NYSE: TOST) shares are trading higher in Thursday's after-hours session after the company reported better-than-expected financial results and
Toast Launches Invoicing To Help Restaurants Grow Their Catering And Events Business
With integrated digital invoicing, Toast streamlines the process of creating customer invoices, collecting payments, prepping and fulfilling orders
Toast (NYSE:TOST), the all-in-one digital platform built for
Toast Gets An Upgrade As Industry Survey Exudes Promise
Mizuho analyst Dan Dolev upgraded Toast, Inc (NYSE:TOST) from Neutral to Buy and raised the price target from $22 to $24. Mizuho’s…
Analyst Ratings for Toast
Over the past 3 months, 10 analysts have published their opinion on Toast (NYSE:TOST) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Mizuho Upgrades Toast to Buy, Raises Price Target to $24
Mizuho analyst Dan Dolev upgrades Toast (NYSE:TOST) from Neutral to Buy and raises the price target from $22 to $24.
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.
Analyst Believes Value Of Core Square Seller, Branded Paypal Checkout, FIS Bank Software Assets ‘Undemanding’
KeyBanc analyst Josh Beck ran a SoTP analysis across extensive cap FinTech and walked away the most positive on Block,…